Durvalumab vs Ranitidine

Durvalumab vs Ranitidine: Overview

This comparison examines the pharmacological differences between Durvalumab and Ranitidine.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Ranitidine: Competitive H2 receptor antagonist.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Ranitidine — 2-3 hours.

Chemical Properties

Molecular Formula: Ranitidine — C13H22N4O3S.

Molecular Weight: Ranitidine — 314.4050 g/mol.

Type: Durvalumab — Antibody; Ranitidine — Small molecule.